Ironwood Pharmaceuticals
Commercial-stage biopharmaceutical company focused on GI diseases, known for LINZESS (linaclotide) for irritable bowel syndrome and chronic constipation. Publicly traded on NASDAQ (IRWD).
Notes
Ironwood Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal (GI) diseases. The company's lead product LINZESS (linaclotide) is a first-in-class guanylate cyclase-C agonist approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).
Founded in 1998 and publicly traded on NASDAQ (ticker: IRWD), Ironwood has built a significant commercial presence in the GI space. LINZESS is co-developed and co-promoted with AbbVie (formerly Allergan) in the United States.
The company continues to develop new products for GI conditions and has expanded its focus to include other areas where guanylate cyclase biology may be relevant.
Team
- Tom McCourt - CEO
- LinkedIn: linkedin.com/in/tommccourt
- Experienced commercial and development leadership team
Additional Research Findings
- Founded in 1998, headquartered in Boston, Massachusetts
- Public company on NASDAQ (ticker: IRWD)
- LINZESS: FDA approved for IBS-C and CIC
- Partnered with AbbVie (formerly Allergan)
- Guanylate cyclase-C agonist platform
- Revenue-generating commercial company
- Backed by Polaris Partners (early investor)
- Multiple GI programs in development
- Over $400 million annual LINZESS revenue
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |